AP-003

BLife Therapeutics is planning clinical trials of AP-003 to test the efficacy of IFNa2b for treatment of COVID-19. AP-003 is being developed as a novel interferon alpha2b (IFNa2b) inhalation formulation.

IFNa2b has been used to treat COVID 19 in China.² Subject to receiving marketing authorization, AP-003 could potentially be used to treat patients early after COVID 19 infection which may potentially prevent the progression to severe disease and need for hospitalization.³

  1. Subject to successful outcome of clinical trials and obtaining market authorization
  2. Dong et al, 2020; Lu, 2020; Shen & Yang, 2020; Zhou et al, 2020
  3. Altum Clin Protocol ALT 003 COV 01 2020 04 30

If successful in clinical trials, AP-003 may potentially be positioned as an initial treatment for COVID 19 and similar viruses.

For more information please see the full investor presentation.

Breaking News

May 12, 2020 The Globe and Mail

Interferon Emerges as Potential Treatment For COVID-19

May 11, 2020 Medscape

Triple Antiviral Combo May Speed COVID-19 Recovery

May 11, 2020 CISION PR Newswire

BetterLife Pharma Highlights Results from Recent Clinical Reports…

May 8, 2020 New York Times

A Drug Cocktail Hastens Recovery in Some Coronavirus…

May 7, 2020 CISION PR Newswire

BetterLife Pharma Enters into a Licensing Agreement

OUR LEADERSHIP TEAM

BetterLife has assembled a highly experienced management team that has clinical, commercial, product development and financial experience